U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1591 - 1600 of 149123 results

Status:
Investigational
Source:
NCT00278980: Phase 2 Interventional Completed Diabetes Mellitus, Type 1
(2003)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:oxisopred
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Oxisopred is a synthetic corticosteroid that has never been marketed. Information about the current use of this compound is not available.
Status:
Investigational
Source:
INN:vemircopan [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:etavopivat [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT03654547: Phase 1 Interventional Active, not recruiting Advanced Solid Tumors
(2019)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
INN:ucasareotide dasaroxetan [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT01327495: Phase 2/Phase 3 Interventional Completed Healthy
(2011)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Merrion Pharmaceuticals was developing an oral tablet formulation of acyline, a gonadotropin-releasing hormone (GnRH) antagonist, referred to as MER 104. MER-104 effectively suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in man. Acyline has been investigated for the prevention and treatment of hypogonadism and contraception. Injectable forms have been administered successfully in man in Phase II studies as part of a potential contraceptive regimen. MER-104 is an enteric coated acyline tablet developed by Merrion Pharmaceuticals using GIPET™ I technology to enable the oral administration of this decapeptide. The development of acyline appears to have been discontinued.
Status:
Investigational
Source:
NCT01861873: Phase 2 Interventional Unknown status Liver Metastases
(2013)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
NCT03020745: Phase 2 Human clinical trial Completed N/A
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Galactosamine is a hexosamine derived from galactose with the molecular formula C6H13NO5. A few amino sugars, including galactosamine, have been shown to kill tumors in the laboratory. It is unlikely to be used in cancer therapy, however. D-galactosamine is a hepatotoxic, or liver-damaging, agent. Researchers studying animal models of liver failure sometimes use D-galactosamine to induce liver damage. Galactosamine is also helpful for researchers studying agents that might protect the liver from damage.
Status:
Investigational
Source:
INN:zeteletinib [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Showing 1591 - 1600 of 149123 results